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The purpose of this study is to evaluate the clinical
usefulness of the cervicogram as a primary screening test for
cervical neoplasia. A total of 294 women who had undergone
a cervicogram and a Pap test between January and July 2003,
were selected. The diagnostic accuracy of the Pap test,
cervicogram, and the Pap test combined with a cervicogram
were compared with the histopathologic diagnosis. Among 294
women, the Pap test was negative in 130 cases and positive
in 164 cases. Among patients with positive Pap test, cervico-
gram were negative in 101 cases (61.6%) and positive in 63
cases (38.4%). The diagnostic accuracy between cervicogram
with positive Pap test and histology was as follows; sensitivity
44.9%, specificity 78.3%, positive predictive value 84.1%,
negative predictive value 32.7%, false positive rate 15.9%, and
false negative rate 67.3%. Although the adjunctive use of
cervicogram with the Pap test in the initial screening of
cervical neoplasia showed a higher specificity and higher
positive predictive value compared to the Pap test alone, con-
sideration in terms of lower sensitivity, lower positive
predictive value, higher false positive rate and cost-effective-
ness should be given in lieu of clinically applying cervicogram
with the pap test as an initial screening test.
Key Words: Cervicogram, primary screening test, diagnostic
accuracy, the Pap test
INTRODUCTION
Cancer of the cervix is the most common form
of cancer for women in developing countries, the
second most frequent cancer worldwide, and the
most frequent gynecological cancer seen in
Korean women.1,2 If cervical carcinoma can be de-
tected early, the prognosis is excellent and com-
plete control may be expected in the premalignant
status.3-5 The Pap test, developed by Papanicolaou
in 1940s, reduced the incidence and mortality rate
of cervical cancer significantly. In the USA, the
Pap test reduced the death rate of cervical cancer
patients by 70% and it presently saves approxi-
mately 10,600 women's lives annually.6 However,
reasonable test performance using a competent
laboratory results in false negative rates of about
15 - 45% for cervical neoplasia, and supplemental
tests that make up for the shortcoming of the
cervico- vaginal method are required.6,7
Since Hans Hinselman in Hamburg, Germany,
applied colposcopy to cervical cancer in 1925,
colposcopy has been used as the other most
required test, together with the Pap test, in the
detection of cervical cancer and premalignant
lesion. The drawbacks of colposcopy, however,
are that a large number of patients can not be
examined as it requires a specialist with great
experience who is excellent in diagnosis. It also
requires expensive equipment. It takes a long time
for diagnosis. Another shortcoming of colposcopy
is the difficulty of its application to general
screening and mass screening, as the equipment
cannot be moved readily.
8,9
Adolf Stafl at the Wisconsin University College
of Medicine, USA, developed cervicography in
1981.
8
The principle of cervicography is based on
colposcopy. However, cervicography obtains ob-
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jective test materials with the use of a special
camera. The procedure is to take pictures of the
outside of cervix, develop the pictures and in-
terpret the pictures. Hence, compared with
colposcopy, the advantages of cervicography are
that it is relatively inexpensive, the equipment can
be moved readily and specialists can perform the
interpretation objectively and reproducibly.10
Cervicography has been reported to be applicable
to mass screening for cervical cancer, and it can
facilitate the selection of therapy for patients with
abnormal cells detected by the Pap test.11
Recently, regardless of the findings of the Pap
test, several institutes have performed cervico-
graphy in combination with the Pap test screen-
ing. Therefore, we evaluated the effectiveness of
applying cervicography in combination with the
Pap test for the primary screening of cervical
neoplasia.
MATERIALS AND METHODS
Materials
Among all patients screened by cervicography
at the Yonsei Cancer Detection Center of the
Department of Obstetrics and Gynecology, Yonsei
University College of Medicine from January to
July 2003, 294 patients who were examined by the
Pap test and cervicography as a screening pro-
cedure for cervical cancer and taken by the
subsequent colposcopy directed biopsy or surgical
resection as required, were analyzed. Patients
whose results of cervicography had a technical
defect were excluded from this study. The mean
age of the subjects was 43 years, and the ages
ranged from 19 years to 83 years.
Methods
The Pap test was performed first, followed by
cervicography. A cytobrush or spatula was used
to obtain specimens for the Pap test. The results
were interpreted according to the Bethesda clas-
sification: negative for intraepithelial lesion or ma-
lignancy (N), atypical squamous cells of undeter-
mined significance (ASC-US), atypical squamous
cells can not exclude HSIL (ASC-H), low-grade
squamous intraepithelial lesion (LSIL), high-
grade squamous intraepithelial lesion (HSIL), and
squamous cell carcinoma (SCC).
Cervicography was performed with a cervis-
cope (NTL lab Ltd, Korea), and we used
Ektachrome film (ASA 200). The procedure was to
insert a speculum, expose the cervix of uterus
adequately, remove mucus or blood with cotton
swabs, apply 5% acetic acid, and examine the
condition of the cervix for 15-20 seconds and note
any discharge and bleeding. After applying the
acetic acid again, the camera was focused and two
cervicograms were taken within 30 seconds. The
results of cervicograms were analyzed by the new
cervicogram program developed in Korea, and
this program was recommended by Korean
Woman's Cancer Research Foundation of Catholic
Medical Center (Table 1).
To analyze the data, the Pap test classified as
atypical squamous cells of undetermined signi-
ficance (ASC-US), atypical squamous cells can not
exclude HSIL (ASC-H), low-grade squamous
intraepithelial lesion (LSIL), high-grade squamous
intraepithelial lesion (HSIL), and squamous cell
carcinoma (SCC) were considered as positive, and
suspicious atypia (S1, S2) and positive (PH, PL,
and PC) on a cervicogram were considered as
positive. The diagnosis of histology above cervical
intraepithelial neoplasia (CIN) I was considered as
positive. Data was analyzed using parametric and
nonparametric statistics, SPSS 10.0 (Chicago, IL,
USA). Differences were considered significant
when the probability of the error was below 5%
(p < 0.05).
RESULTS
The result of screening tests and histology
Among 294 women, the Pap test was negative
for intraepithelial lesion or malignancy in 130
cases (44.2%), ASC-US in 45 cases (15.3%), ASC-H
in 4 cases (1.4%), LSIL in 46 cases (15.6%), HSIL
in 46 cases (15.6%), and SCC in 23 cases (7.8%).
Cervicographies were negative (N1, N2) in 55
cases (18.7%), benign atypia (B1, B2) in 147 cases
(50.0%), suspicious atypia (S1, S2) in 80 cases
(27.2%), and positive (PH, PL, PC) in 12 cases
Location
Table 1. Evaluation Report-Cervicogram-Slide New Cervicography System
A. Adequacy of the Cervicogram for evaluation
Satisfactory for evaluation: visible SCJ and Transformation Zone (T-Zone) ( )
Satisfactory for evaluation: visible SCJ but no T-Zone visible ( )
Unsatisfactory for evaluation: Both SCJ and T-Zone are visible acetowhite ( )
B. Findings/cervicogram-Descriptive diagnosis
Negative-no definite lesion, routine basis-screening
N-1. ___Components of T-zone are visible
N-2. ___Components of T-zone are visible-endocervical cytology/HPV test
Benign Atypical-A Cervicogram picture, cytology, and HPV Test are recommended in 3___, 6___ , 12___, months
B-1. ___A lesion of doubtful significance is visible inside the T-zone
B-2. ___A lesion of doubtful significance is visible outside the T-zone
Suspicious Atypical-Probable normal variant, but repeat cervicography and HPV Test in 1___, or 3___month, and
colposcopy is recommended to exclude significant disease (hall markers or positive lesions)
S1___ 1 month ___ 3month ___ repeat cervicography
S2___ colposcopy and biopsy
Positive-Colposcopy and biopsy is recommended
PL ___ Compatible with low grade lesion A __ B __
PH ___ Compatible with high grade lesion
PC ___ Compatible with invasive cancer
Unsatisfactory-Cervicography again( )
UT __ Technical defect, UO __ Others (Info ___, anatomic ____ )
Other ___ non epitheliological disease or malignancy e.g. sarcoma
Vulva( ), Vagina( ), Urethra( )
Definition of Evaluation Report-Terminologies and Classifications
Adequacy of the Cervicogram for evaluation
Visibility of SCJ (Congenital and secondary) and T-zone is very important for satisfactory evaluation
Findings of Cervicogram
Negative - no definite lesion are visible
Benign atypical - character of the lesion in terms of site and morphology is considered presently to be of nonspecific
significance
Suspicious atypical - although some of hall markers are visible, the lesion is considered probable normal variants.
Colposcopy, however, is recommendable immediately or certain period of observation to exclude significant
disease.
Positive - character of the lesion in term of site and morphology is considered, the appearance warrants colposcopy
to exclude significant disease
A. A lesion extending into the canal, the visible portion of which is presently considered to be of doubtful significance.
B. A lesion compatible with low-grade intraepithelial disease.
Unsatisfactory for Evaluation of the Cervicogram
TD - not adequate for evaluation by technical defect
UO- not adequate by other reason, Inflammation, anatomic defect etc
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Location
Acetowhite epithelium
Punctation
Erosion or ulcer
Discoloration
Mosaic
Atypical vessels
Irregular surface
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(4.1%). The histopathological diagnosis were
cervicitis in 131 cases (44.6%), CIN I in 48 cases
(16.3%), CIN II in 11 cases (3.7%), CIN III in 25
cases (8.5%), carcinoma in situ of cervix in 31
cases (10.5%), and invasive cervical carcinoma in
48cases (16.3%) (Table 2).
The correlation of screening tests and histology
Among 294 women, the Pap test was negative
in 130 cases (44.2%) and positive in 164 cases
(55.8%). The sensitivity of the Pap test was 72.0%,
the specificity was 64.6%, the positive predictive
value was 72.0%, the negative predictive value
was 64.6%, the false positive rate was 28.0%, and
the false negative rate was 35.4%. The instances of
a positive result on the Pap test and negative in
histology were 46 cases (15.6 %). The instances of
a negative result on the Pap test and positive on
the histology were 46 cases (15.6%). The cervico-
graphies were negative in 202 cases (68.7%) and
positive in 92 cases (31.3%). The sensitivity of
cervicography was 39.6%, the specificity was
79.2%, the positive predictive value was 70.7%,
the negative predictive value was 31.0%, the false
positive rate was 29.3%, and the false negative
rate was 49.0%. The instances of a positive result
on cervicography and a negative result on his-
tology were 27 cases (9.2%), and the instance of
a negative result on cervicography and a positive
result on histology were 99 cases (33.7%). 101
cases (34.4%) were normal by both tests, and 193
cases (65.6%) were positive by either of the two
screening tests. When combining the two scre-
ening tests, the sensitivity was 79.3%, the speci-
ficity was 51.5%, the positive predictive value was
Table 2. Outcome of Screening Tests and Histology
Screening tests Result No. of cases Percent (%)
Pap smear
Negative N 130 44.2
Positive ASC-US 45 15.3
ASC-H 4 1.4
LSIL 46 15.6
HSIL 46 15.6
SCC 23 7.8
Cervicogram
Negative N1, N2 55 18.7
B1, B2 147 50.5
Positive S1, S2 80 27.2
PL, PH, PC 12 4.1
Histology
Negative CNI 131 44.6
Positive CIN I 48 16.3
CIN II 11 3.7
CIN III 25 8.5
CIS 31 10.5
SCC 48 16.3
Total 294 100.0
N, negative for intraepithelial lesion or malignancy; ASC-US, atypical squamous cells of undetermined significance; ASC-H, atypical
squamous cells can not exclude HSIL; LSIL, low-grade squamous intraepithelial lesion; HSIL, high-grade squamous intraepithelial
lesion; SCC, squamous cell carcinoma; CIN, cervical intraepithelial neoplasia.
Cervicogram as a Primary Screening Test
Yonsei Med J Vol. 46, No. 2, 2005
67.4%, the negative predictive value was 66.3%,
the false positive rate was 32.6%, and the false
negative rate was 33.7%. The instances of a
positive result on both screening tests, but with a
negative result on histology were 63 cases (21.4%).
34 cases (11.6%) were negative on both tests and
positive on histology (Table 3, 5).
Table 3. Correlation between Screening Tests and Histological Findings
Histology
Total
Negative Positive
Pap smear Negative 84 46 130
Positive 46 118 164
Cervicogram Negative 103 99 202
Positive 27 65 92
Pap smear + Negative 67 34 101
Cervicogram Positive 63 130 193
Total 130 164 294
Table 5. Diagnostic Accuracy of Screening Methods
Pap smear Cervicogram Pap smear+Cervicogram
Cervicogram
Negative Pap smear Positive Pap smear
Sensitivity 72.0% 39.6% 79.3% 26.1% 44.9%
Specificity 64.6% 79.2% 51.5% 79.8% 78.3%
PPV 72.0% 70.7% 67.4% 41.4% 84.1%
NPV 64.6% 31.0% 66.3% 66.3% 32.7%
FPR 28.0% 29.3% 32.6% 58.6% 15.9%
FNR 35.4% 49.0% 33.7% 33.7% 67.3%
PPV, positive predictive value; NPV, negative predictive value; FPR, false positive rate; FNR, false negative rate.
Table 4. Correlation between Cervicogram and Histological Findings
Histology
p
Negative Positive
Normal Pap smear
Cervicogram Negative 67 34
Positive 17 12 NS
Total 84 46
Abnormal Pap smear
Cervicogram Negative 36 65
Positive 10 53 NS
Total 46 118
NS, not significant.
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The correlation of cervicography based on Pap
smear and histology
For 130 women with negative Pap test, 101
cases (77.7%) were negative and 29 cases (22.3%)
were positive on cervicography. For patients with
negative Pap test, the sensitivity of cervicography
was 26.1%, the specificity was 79.8%, the positive
predictive value was 41.4%, the negative predic-
tive values was 66.3%, the false positive rate was
58.6%, and the false negative rate was 33.7%. For
women with negative Pap test, the instances of a
positive result on cervicography and a negative
result on histology were 17 cases (13.1%), and the
instances of a negative result on cervicography
and a positive result on histology were 34 cases
(26.2%). For 164 women with positive Pap test,
101 cases (61.6%) were negative and 63 cases
(38.4%) were positive on cervicography. For
women with positive Pap test, the sensitivity of
cervicography was 44.9%, the specificity was
78.3%, the positive predictive value was 84.1%,
the negative predictive value was 32.7%, the false
positive rate was 15.9%, and the false negative
rate was 67.3%. For women with positive Pap test,
the instances of a positive result on cervicography
and a negative result on histology were 10 cases
(6.1%), and the instances of a negative result on
cervicography and a positive result on histology
were 65 cases (39.6%) (Table 4, 5).
Comparison of diagnostic accuracy according to
screening tests
Compared with the Pap test, the diagnostic
accuracy of cervicography was inferior because of
its lower sensitivity, positive/negative predictive
value and higher false positive/negative, even if
its specificity was higher. Combining the two
screening tests may be partially helpful as the
sensitivity of the combined screening tests was
higher than the Pap test alone, and together the
two tests had a higher negative predictive value
and lower false negative rate. Because of its low
specificity and low positive predictive value,
however, and considering its cost and effectiv-
eness together, the combined tests have limita-
tions as screening tests. We assessed the accuracy
of cervicography even in the patients that were
classified based on their Pap test results, and
although the specificity was slightly higher
(79.8%, 78.3% > 64.6%) and the sensitivity was
lower (26.1%, 44.9% < 72.0%), the positive/nega-
tive predictive value and the false positive/nega-
tive rate were not significantly different.
The consistency of cervicography for Pap test
was analyzed with Kappa test, and the result was
fair (κ=0.71).
DISCUSSION
Cervical cancer is the most common cancer in
the reproductive organs of women. Over 450,000
new cases were detected annually, and over
230,000 women die due to this disease with 80%
of these deaths occurring in developing coun-
tries.1,2 In developed countries, where the scre-
ening program has been actively applied, the
incidence as well as the mortality rate has been
decreased significantly.12-15 The significant de-
creases in cervical cancer incidence and mortality
can be largely attributed to the success of
widespread Pap test. The onset and the natural
history of cervical cancer are well established. In
addition, the early diagnosis of cervical cancer is
feasible as its primary lesion is readily accessible.
Therefore, cervical cancer is a curable disease if
the appropriate treatments are administered at the
early stage of disease.
Over the past several decades, numerous
studies have been performed to develop screening
methods for cervical cancer, and presently, re-
search is actively ongoing to develop methods
that will allow doctors to detect premalignant
lesions effectively. The Pap test that was devel-
oped in 1942 is currently the most frequently and
widely used method worldwide as an individual
screening test and as a mass-screening test. Never-
theless, its shortcomings of the low sensitivity and
the high false-negative results (15-45%) have been
reported,7,8 and the main factors contributing to
the false-negative rate were specimen collection,
laboratory error, and deficiencies in laboratory
quality assurance system.16-18 Giles et al. reported
that the Pap test failed to detect approximately
30% of invasive cancer and 58% of premalignant
lesion of the uterine cervix.19
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Hans Hinselman in Hamburg, Germany applied
colposcopy to the screening of cervical cancer for
the first time in 1925. The advantages of colpos-
copy are its ability to locate the low infiltrated
lesions, to determine the extent of the lesions, and
its high accuracy. Colposcopy has been used
widely as a diagnostic tool, together with the Pap
test, for cervical cancer and premalignant lesions.
However, high false positive rates for colposcopy
have been reported. Although this is due to the
interpretation skill of specialists, it is also influ-
enced by trichomonas or papilloma virus infec-
tion.20 The limitations of colposcopy are that it re-
quires experienced specialists with excellent in-
terpretation skills, it requires expensive equip-
ments, and only a limited number of patients can
be examined as the test takes a long time. Fur-
thermore, as the equipments cannot be moved
readily, its application to mass screening and
general screening is limited.8,9
Cervicography is a screening method developed
in 1981 by Adolf Stafl in the Wisconsin University
College of Medicine.8,21,22 Although its principles
are based on colposcopy, cervicography obtains
objective test materials with a special camera by
taking pictures of the outside of cervix, deve-
loping the pictures, and then interpreting the
pictures by 2 - 3 cervicography specialists. Com-
pared with colposcopy, the advantages of cervi-
cography are that it is relatively inexpensive, the
equipment is moved readily, the image can be
objectively interpreted by experienced specialists,
and the method has high reproducibility.
10
Thus,
cervicography has been reported to be applicable
to mass screening for cervical cancer and to
facilitate the selection of therapy for patients with
atypical cells detected by the Pap test.11 In scre-
ening for cervical cancer by cervicography, techni-
cal defects were detected in about 1-10% cases.
This is primarily due to blood masking the view
of the cervix. The disadvantage of cervicography
is its high false positive rate: 26-38.1% false
positives have been reported. In our study, the
false positive rate was 29.3%.23-25 Other disadvan-
tages are its limitation in examining the cervical
canal and tissue specimens cannot be obtained.6
The advantage of the Pap test is its ability to
obtain cervical epithelial cells. However, as
specimens from a large area of the cervix cannot
be obtained, the cervico-vaginal smear may gener-
ate the false negative results. In contrast, cervico-
graphy can verify a small pathological lesion. The
shortcomings of cervicography are that it can not
examine the inside of cervix and its effectiveness
is decreased in old patients whose transitional
zone can not be visualized or in patients whose
cervix has been previously treated. Therefore, it
has been reported that the supplemental use of
these two tests is advantageous and the combina-
tion of the two tests is expected to reduce the false
negative rate and increase the detection rate.25,26
In our study, however, the sensitivity of cervi-
cography was 39.6% lower than the Pap test. In
addition, the false negative rate of cervicography
was higher than the Pap test (49% vs. 35.4%).
Therefore, cervicography could not overcome the
disadvantages of the Pap test, although the speci-
ficity of cervicography was higher than the
specificity of the Pap test (79.2% vs. 64.6%). For
the combination of the Pap test with cervico-
graphy, compared with the Pap test alone, the
sensitivity was higher (79.3% vs. 72.0%), the
negative predictive value was higher (66.3% vs.
64.6%), and the false negative rate was lower
(33.7% vs. 35.4%). Yet, the difference was not
statistically significant.
For the combination of the two tests, however,
the specificity was lower (51.4% vs. 64.6%), the
positive predictive value was lower (64.7% vs.
72%), and the false positive rate was higher (32.6%
vs. 28%). Concerning the cost and the effectiv-
eness, the combination of two tests as a primary
screening method may be require its reconsi-
deration for clinical application. When comparing
the effectiveness of cervicography on the patients
classified based on their Pap test results, its
diagnostic accuracy was not superior, except for
the specificity. For patients with a normal Pap test
and with cytology testing performed on those
patients with positive cervicography, the false
positive rate was as high as 58.6% and the
sensitivity rate was low, 26.1%. The data showed
that unnecessary cervical biopsy was performed
in many cases. In patients with positive Pap test,
on the other hand, the false negative rate was
67.3% on cervicography. Thus, for patients with
negative cervicography, without additional tests,
pathological lesions were not detected in many
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cases.
In conclusion, application of cervicography as
primary screening test in conjunction with the Pap
test may be slightly helpful as the specificity was
increased, the negative predictive value was in-
creased, and the false negative rate was decreased.
Nevertheless, when consideration is given in
terms of its low sensitivity, low positive predictive
value and high false positive rate, the clinical
application of cervicography with the Pap test as
primary screening tests requires further research
regarding the cost and effectiveness.
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